News
GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.
Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...
A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...
Essex Live on MSN9h
'I tried classic pie and mash for the first time and was pleasantly surprised despite unappealing appearance'Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Health on MSN6d
Road to Diagnosis: My Doctors' Focus on My Weight Delayed My MASH Diagnosis for YearsAroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...
Annual Congress, CureGene Pharmaceuticals ("CureGene") announced late-breaking preclinical results for its investigational liver-targeted thyroid hormone receptor beta (THR-β) prodrug, CG-0416.
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...
Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback